Status:
COMPLETED
EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Diabetes Mellitus Type II
Eligibility:
All Genders
35-50 years
Phase:
NA
Brief Summary
The aim of this study is to determining of the effects of Eicosapentaenoic acid (EPA) supplementation on serum activities of Paraoxonase-1 and Homocystein thiolactonase, and serum levels of some indic...
Detailed Description
The aim of this study is to determining of the effects of Eicosapentaenoic acid (EPA) supplementation on serum activities of Paraoxonase-1 and Homocystein thiolactonase and several indicators of vascu...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Willingness to collaborate in the study
- aged 35-50 years
- having a history of at least 1 year of type 2 diabetes mellitus before the participation in the study based on FBS ≥126 mg/dl or 2hPG ≥200 mg/dl (2-hour plasma glucose),
- 25≤BMI\<30 kg/m2
- Exclusion criteria:
- pregnant and breastfeeding women
- using insulin, alcohol consumption, smoking and other drugs
- taking drugs (lipid-lowering, β-blockers, diuretics, estrogens, progesterones, vitamin supplements and ω-3 fatty acid supplements
- followers of the special diet
- history of diabetic retinopathy or diabetic nephropathy
- type 1 diabetes mellitus and other disorders
- any need to take insulin, change in the dose (s) and type of medication or physical activity
Exclusion
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03258840
Start Date
January 1 2013
End Date
August 1 2014
Last Update
August 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tehran University of Medical Sciences (TUMS), School of Nutritional Sciences and Dietetics, Department of Cellular and Molecular Nutrition
Tehran, Iran, 1471613151